MX2022014387A - Vacunas contra coronavirus a base de vaccinia ankara sintetica modificada (smva). - Google Patents
Vacunas contra coronavirus a base de vaccinia ankara sintetica modificada (smva).Info
- Publication number
- MX2022014387A MX2022014387A MX2022014387A MX2022014387A MX2022014387A MX 2022014387 A MX2022014387 A MX 2022014387A MX 2022014387 A MX2022014387 A MX 2022014387A MX 2022014387 A MX2022014387 A MX 2022014387A MX 2022014387 A MX2022014387 A MX 2022014387A
- Authority
- MX
- Mexico
- Prior art keywords
- modified vaccinia
- smva
- vaccinia ankara
- mva
- vaccines
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20071—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063026127P | 2020-05-17 | 2020-05-17 | |
| US202063044033P | 2020-06-25 | 2020-06-25 | |
| US202063113810P | 2020-11-13 | 2020-11-13 | |
| US202163161371P | 2021-03-15 | 2021-03-15 | |
| PCT/US2021/032821 WO2021236550A1 (en) | 2020-05-17 | 2021-05-17 | Synthetic modified vaccinia ankara (smva) based coronavirus vaccines |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022014387A true MX2022014387A (es) | 2023-04-11 |
Family
ID=78708032
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022014387A MX2022014387A (es) | 2020-05-17 | 2021-05-17 | Vacunas contra coronavirus a base de vaccinia ankara sintetica modificada (smva). |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US20230323389A1 (enExample) |
| EP (1) | EP4153228A4 (enExample) |
| JP (2) | JP7788403B2 (enExample) |
| KR (1) | KR20230012583A (enExample) |
| CN (1) | CN116348132A (enExample) |
| AU (1) | AU2021276265A1 (enExample) |
| BR (1) | BR112022023173A2 (enExample) |
| CA (1) | CA3183016A1 (enExample) |
| IL (1) | IL298210A (enExample) |
| MX (1) | MX2022014387A (enExample) |
| WO (1) | WO2021236550A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3167052A1 (en) | 2020-02-14 | 2021-08-19 | Mary Jo Hauser | Vaccines and uses thereof to induce an immune response to sars-cov2 |
| EP4153228A4 (en) | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| TW202330575A (zh) * | 2021-09-29 | 2023-08-01 | 瑞典商斯文斯卡疫苗生產股份有限公司 | 用於治療及預防冠狀病毒之組成物及方法 |
| US20250235527A1 (en) * | 2021-11-17 | 2025-07-24 | City Of Hope | Synthetic modified vaccinia ankara (smva) based coronavirus vaccines |
| CN117384864A (zh) * | 2022-07-11 | 2024-01-12 | 清华大学 | 表达SARS-CoV-2 Omicron Spike蛋白的重组腺病毒及其应用 |
| EP4558171A1 (en) * | 2022-07-22 | 2025-05-28 | City of Hope | Synthetic modified vaccinia ankara vaccines to stimulate orthopox and monkeypox virus immunity |
| EP4316514A1 (en) * | 2022-08-03 | 2024-02-07 | Consejo Superior de Investigaciones Científicas (CSIC) | Mva-based vectors and their use as vaccine against sars-cov-2 |
| TW202426045A (zh) * | 2022-10-07 | 2024-07-01 | 高端疫苗生物製劑股份有限公司 | 抗新型冠狀病毒(SARS-CoV-2) Omicron變異株之免疫組合物 |
| WO2026030724A1 (en) * | 2024-08-01 | 2026-02-05 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Sars-cov-2 vaccine |
| WO2026087525A1 (en) | 2024-10-21 | 2026-04-30 | Julius-Maximilians-Universität Würzburg, In Vertretung Des Freistaates Bayern | A deliverable cytosolic gene expression system based on poxviral rna polymerase and dna templates |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2431349A1 (en) | 2002-06-06 | 2003-12-06 | Xiao-Dan Yao | Method of producing a recombinant virus |
| JP5052893B2 (ja) | 2003-02-20 | 2012-10-17 | アメリカ合衆国 | ポックスベクターにおける新規の挿入部位 |
| WO2005016238A2 (en) * | 2003-05-08 | 2005-02-24 | Duke University | Severe acute respiratory syndrome |
| EP1678292A4 (en) * | 2003-09-18 | 2008-05-07 | Univ Emory | IMPROVED MVA VACCINES |
| WO2006071250A2 (en) * | 2004-04-05 | 2006-07-06 | Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Soluble fragments of the sars-cov spike glycoprotein |
| DK2402451T3 (en) | 2006-08-25 | 2018-06-25 | The Government Of The Us Secretary Department Of Health And Human Services | Method for Stabilizing a DNA Insert in a Recombinant Vaccine Vector |
| WO2011047324A1 (en) | 2009-10-16 | 2011-04-21 | The U.S.A. As Represented By The Secretary , Department Of Health And Human Services . | Recombinant modified vaccinia ankara (mva) vaccinia virus containing restructured insertion sites |
| US20210260181A1 (en) * | 2014-09-16 | 2021-08-26 | Altimmune, Inc | Coronavirus immunogenic compositions and uses thereof |
| EP3045181B1 (en) * | 2015-01-19 | 2018-11-14 | Ludwig-Maximilians-Universität München | A novel vaccine against the middle east respiratory syndrome coronavirus (MERS-CoV) |
| AU2017272721B2 (en) | 2016-05-30 | 2023-03-30 | Astellas Pharma Inc. | Novel genetically engineered vaccinia viruses |
| IL319942A (en) | 2016-11-02 | 2025-05-01 | Evans David | Synthetic chimeric poxviruses, methods for their production, compositions containing them and uses thereof |
| KR20240113607A (ko) | 2017-06-21 | 2024-07-22 | 트랜스진 | 개인 맞춤형 백신 |
| WO2019014569A1 (en) * | 2017-07-13 | 2019-01-17 | City Of Hope | EXPRESSION SYSTEM FOR EXPRESSING GLYCOPROTEIN COMPLEXES OF HERPESVIRUS |
| CA3099330A1 (en) * | 2018-05-02 | 2019-11-07 | Tonix Pharma Holdings Limited | Synthetic chimeric vaccinia virus |
| TW202204380A (zh) | 2020-01-31 | 2022-02-01 | 美商詹森藥物公司 | 用於預防及治療冠狀病毒感染之組合物及方法－sars-cov-2疫苗 |
| CN115397998A (zh) | 2020-02-03 | 2022-11-25 | 希望之城 | 由天然或合成dna产生的基于痘病毒的载体及其用途 |
| DE202021004130U1 (de) | 2020-02-04 | 2022-10-26 | Curevac Ag | Coronavirus-Vakzine |
| BR112022016054A2 (pt) * | 2020-02-14 | 2022-10-11 | Altimmune Inc | Composições imunogênicas para coronavírus e usos das mesmas |
| CA3167052A1 (en) | 2020-02-14 | 2021-08-19 | Mary Jo Hauser | Vaccines and uses thereof to induce an immune response to sars-cov2 |
| GB2594683A (en) | 2020-02-17 | 2021-11-10 | Vaxbio Ltd | Vaccine |
| BR112022016992A2 (pt) * | 2020-02-26 | 2022-10-25 | Tonix Pharma Ltd | Vacina com base em poxvírus recombinante contra ví-rus sars-cov-2 |
| WO2021178416A1 (en) * | 2020-03-02 | 2021-09-10 | Heat Biologics, Inc. | Immune-mediated coronavirus treatments |
| US11202753B1 (en) * | 2020-03-06 | 2021-12-21 | Aquavit Pharmaceuticals, Inc. | Systems and methods for generating immune responses in subjects using microchannel delivery devices |
| KR20220152248A (ko) | 2020-03-13 | 2022-11-15 | 옥스포드 유니버시티 이노베이션 리미티드 | 면역 반응을 유도하기 위한 조성물 및 방법 |
| TW202203966A (zh) | 2020-03-31 | 2022-02-01 | 澳大利亞商賽門蒂斯公司 | 用於防範ｃｏｖｉｄ－１９之以減毒的痘病毒載體為底質之疫苗 |
| WO2021216743A2 (en) | 2020-04-21 | 2021-10-28 | Emory University | Coronavirus vaccines, compositions, and methods related thereto |
| EP4153228A4 (en) | 2020-05-17 | 2024-07-10 | City of Hope | CORONAVIRUS VACCINES BASED ON SYNTHETIC MODIFIED ANKARA VACCINE (SMVA) VIRUS |
| US20220370600A1 (en) * | 2021-05-21 | 2022-11-24 | Board Of Regents, The University Of Texas System | Multigenic mva-sars-cov-2 vaccine |
-
2021
- 2021-05-17 EP EP21809653.5A patent/EP4153228A4/en active Pending
- 2021-05-17 BR BR112022023173A patent/BR112022023173A2/pt unknown
- 2021-05-17 AU AU2021276265A patent/AU2021276265A1/en active Pending
- 2021-05-17 MX MX2022014387A patent/MX2022014387A/es unknown
- 2021-05-17 IL IL298210A patent/IL298210A/en unknown
- 2021-05-17 CN CN202180059838.6A patent/CN116348132A/zh active Pending
- 2021-05-17 KR KR1020227044240A patent/KR20230012583A/ko active Pending
- 2021-05-17 JP JP2022570108A patent/JP7788403B2/ja active Active
- 2021-05-17 CA CA3183016A patent/CA3183016A1/en active Pending
- 2021-05-17 WO PCT/US2021/032821 patent/WO2021236550A1/en not_active Ceased
- 2021-05-17 US US17/999,170 patent/US20230323389A1/en active Pending
-
2025
- 2025-04-18 US US19/183,257 patent/US12584146B2/en active Active
- 2025-12-08 JP JP2025238238A patent/JP2026041921A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2026041921A (ja) | 2026-03-10 |
| BR112022023173A2 (pt) | 2022-12-27 |
| WO2021236550A1 (en) | 2021-11-25 |
| CA3183016A1 (en) | 2021-11-25 |
| JP7788403B2 (ja) | 2025-12-18 |
| US12584146B2 (en) | 2026-03-24 |
| EP4153228A1 (en) | 2023-03-29 |
| JP2023526073A (ja) | 2023-06-20 |
| US20250313858A1 (en) | 2025-10-09 |
| KR20230012583A (ko) | 2023-01-26 |
| CN116348132A (zh) | 2023-06-27 |
| AU2021276265A1 (en) | 2022-12-08 |
| US20230323389A1 (en) | 2023-10-12 |
| IL298210A (en) | 2023-01-01 |
| EP4153228A4 (en) | 2024-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022023173A2 (pt) | Vacinas contra coronavírus com base na vacínia ankara (smva) modificada sintética | |
| CO2022010342A2 (es) | Composiciones y métodos para modular simultáneamente la expresión de genes | |
| PA8596001A1 (es) | Inhibidores de la arn polimerasa dependiente de arn del virus de la hepatitis c y composiciones y tratamientos que los usan | |
| ECSP12011685A (es) | Inmunoconjugados dirigidos | |
| PE20230171A1 (es) | Vacunas contra el coronavirus y metodos de uso | |
| CO2021005066A2 (es) | Vacuna de ibv 4/91 con proteína espicular heteróloga | |
| MX2013010620A (es) | Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo. | |
| MX2022010588A (es) | Vacuna basada en poxvirus recombinantes contra el virus sars-cov-2. | |
| CO2021011892A2 (es) | Arn terapéutico para el cáncer de próstata | |
| AR109538A1 (es) | Vacuna contra la gripe porcina | |
| MX2021013698A (es) | Composiciones y metodos para el tratamiento de la infeccion por virus de la hepatitis b (vhb). | |
| CL2021003211A1 (es) | Una cepa viva modificada, del virus del síndrome respiratorio y reproductivo porcino (prrs), vacuna que lo comprende y su uso para tratar el prrs tipo ii. (divisional solicitud no. 2123-2018) | |
| MX2021004859A (es) | Vacuna de ibv h52 con proteina espicular heterologa. | |
| AR127858A1 (es) | VACUNAS DE ÁCIDOS NUCLEICOS PARA EL CORONAVIRUS BASADAS EN SECUENCIAS DERIVADAS DE LA CEPA ÓMICRON DEL SARS-CoV-2 | |
| MX2020009262A (es) | Vectores de parapoxvirus. | |
| BR112022014738A2 (pt) | Vetores à base de poxvírus produzidos por dna natural ou sintético e usos dos mesmos | |
| MX2018015506A (es) | Vacuna contra virus de bronquitis infecciosa. | |
| CL2021003063A1 (es) | Arn terapéutico para cáncer de ovario | |
| BRPI0508064A (pt) | flavivìrus, composição de vacina e molécula de ácido nucléico | |
| CL2023003123A1 (es) | Métodos de identificación de pacientes con posibilidad de beneficiarse de tratamiento con inhibidor de telomerasa | |
| MX2019003317A (es) | Metodo para tratar cancer usando una combinacion de agentes que dañan adn e inhibidores de proteina cinasa dependiente de adn (adn-pk). | |
| DK1425404T3 (da) | Vaccinia-MVA-E3L-mutanter og anvendelse deraf | |
| DE602004027767D1 (de) | Promotoren zur Expression in modifiziertem Vaccinia Virus Ankara | |
| MX2026001148A (es) | Vacuna ibv con proteina de espicula dmv/1639 heterologa | |
| MX2022006812A (es) | Metodos para tratar epoc mediante la administracion de un antagonista de il-33. |